Left ventricular functional assessment in murine models of ischemic and dilated cardiomyopathy using [18F]FDG-PET: Comparison with cardiac MRI and monitoring erythropoietin therapy

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-9

  Brunner, Stefan ^a   Todica, Andrei ^a   Böning, Guido ^a   Nekolla, Stefan G ^b   Wildgruber, Moritz ^b   Lehner, Sebastian ^a   Sauter, Martina ^c   Übleis, Christopher ^a   Klingel, Karin ^c   Cumming, Paul ^d   Franz, Wolfgang Michael ^a   Hacker, Marcus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d ABX GmbH   (Germany)

Author keywords

Cardiomyopathy; Ejection fraction; Erythropoietin; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GATED IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; COMPUTED TOMOGRAPHY SCANNER; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; COXSACKIE VIRUS B; DRUG MONITORING; DRUG UPTAKE; ELECTROCARDIOGRAPH; FIBROSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART PROTECTION; INTERMETHOD COMPARISON; ISCHEMIC CARDIOMYOPATHY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEASUREMENT ACCURACY; MOUSE; MYOCARDITIS; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARD; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84875334672     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-43     Document Type: Article

References (35)

1. Sharir T, Germano G, Kavanagh PB, Lai S, Cohen I, Lewin HC, Friedman JD, Zellweger MJ, Berman DS: Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999, 100:1035-1042.
2. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987, 76:44-51.
3. Lorenz JN, Robbins J: Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol 1997, 272:H1137-H1146.
4. Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR, Hunter JJ, Chien KR, Ross J Jr: Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 1996, 94:1109-1117.
5. Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Stork S: Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging 2006, 22:407-416.
6. Hacker M, Stork S, Stratakis D, Angermann CE, Huber R, Hahn K, Tausig A: Relationship between right ventricular ejection fraction and maximum exercise oxygen consumption: a methodological study in chronic heart failure patients. J Nucl Cardiol 2003, 10:644-649.
7. Sibille L, Bouallegue FB, Bourdon A, Micheau A, Vernhet-Kovacsik H, Mariano-Goulart D: Comparative values of gated blood-pool SPECT and CMR for ejection fraction and volume estimation. Nucl Med Commun 2011, 32:121-128.
8. Gropler RJ, Beanlands RS, Dilsizian V, Lewandowski ED, Villanueva FS, Ziadi MC: Imaging myocardial metabolic remodeling. J Nucl Med 2010, 51(Suppl 1):88S-101S.
9. Higuchi T, Nekolla SG, Jankaukas A, Weber AW, Huisman MC, Reder S, Ziegler SI, Schwaiger M, Bengel FM: Characterization of normal and infarcted rat myocardium using a combination of small-animal PET and clinical MRI. J Nucl Med 2007, 48:288-294.
10. Kreissl MC, Wu HM, Stout DB, Ladno W, Schindler TH, Zhang X, Prior JO, Prins ML, Chatziioannou AF, Huang SC, Schelbert HR: Noninvasive measurement of cardiovascular function in mice with high-temporalresolution small-animal pet. J Nuc Med 2006, 47:974-980.
11. Yang Y, Rendig S, Siegel S, Newport DF, Cherry SR: Cardiac PET imaging in mice with simultaneous cardiac and respiratory gating. Phys Med Biol 2005, 50:2979-2989.
12. Stegger L, Heijman E, Schafers KP, Nicolay K, Schafers MA, Strijkers GJ: Quantification of left ventricular volumes and ejection fraction in mice using PET, compared with MRI. J Nuc Med 2009, 50:132-138.
13. Brunner S, Huber BC, Weinberger T, Vallaster M, Wollenweber T, Gerbitz A, Hacker M, Franz WM: Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction. J Cell Mol Med 2012, 16:152-159.
14. Brunner S, Winogradow J, Huber BC, Zaruba MM, Fischer R, David R, Assmann G, Herbach N, Wanke R, Mueller-Hoecker J, Franz WM: Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J 2009, 23:351-361.
15. Hirose S, Takahashi M, Ogawa R, Morimoto H, Izawa A, Sato H, Ise H, Hongo M, Ikeda U: Erythropoietin attenuates the development of experimental autoimmune myocarditis. Cardiovasc Drugs Ther 2007, 21:17-27.
16. Mitsuma W, Ito M, Kodama M, Fuse K, Okamura K, Minagawa S, Kato K, Hanawa H, Toba K, Nakazawa M, Aizawa Y: Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 2006, 344:987-994.
17. Deindl E, Zaruba MM, Brunner S, Huber B, Mehl U, Assmann G, Hoefer IE, Mueller-Hoecker J, Franz WM: G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 2006, 20:956-958.
18. Kandolf R, Hofschneider PH: Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci USA 1985, 82:4818-4822.
19. Rutschow S, Leschka S, Westermann D, Puhl K, Weitz A, Ladyszenskij L, Jaeger S, Zeichhardt H, Noutsias M, Schultheiss HP, Tschope C, Pauschinger M: Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis-ongoing inflammation and an imbalance of the matrix degrading system. Eur J Pharmacol 2010, 630:145-151.
20. Yang Y, Tai YC, Siegel S, Newport DF, Bai B, Li Q, Leahy RM, Cherry SR: Optimization and performance evaluation of the microPET II scanner for in vivo small-animal imaging. Phys Med Biol 2004, 49:2527-2545.
21. Croteau E, Benard F, Cadorette J, Gauthier ME, Aliaga A, Bentourkia M, Lecomte R: Quantitative gated pet for the assessment of left ventricular function in small animals. J Nuc Med 2003, 44:1655-1661.
22. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, Van Train KF, Berman DS: Automatic quantification of ejection fraction from gated myocardial perfusion spect. J Nucl Med 1995, 36:2138-2147.
23. Germano G, Kavanagh PB, Slomka PJ, Van Kriekinge SD, Pollard G, Berman DS: Quantitation in gated perfusion spect imaging: the Cedars-Sinai approach. J Nucl Cardiol 2007, 14:433-454.
24. Nekolla SG, Miethaner C, Nguyen N, Ziegler SI, Schwaiger M: Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med. 1998, 25:1313-1321.
25. Wollenweber T, Zach C, Rischpler C, Fischer R, Nowak S, Nekolla SG, Grobner M, Ubleis C, Assmann G, La Fougere C, Boning G, Cumming P, Franz WM, Hacker M: Myocardial perfusion imaging is feasible for infarct size quantification in mice using a clinical single-photon emission computed tomography system equipped with pinhole collimators. Mol Imaging Biol 2010, 12:427-434.
26. Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K: Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol 2006, 169:2085-2093.
27. Bland JM, Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8:135-160.
28. Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, Edenbrandt L, Flotats A, Germano G, Stopar TG, Franken P, Kelion A, Kjaer A, Le Guludec D, Ljungberg M, Maenhout AF, Marcassa C, Marving J, McKiddie F, Schaefer WM, Stegger L, Underwood R: EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging 2008, 35:851-885.
29. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E: Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005, 19:1323-1325.
30. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, ArcasoyMO: Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004, 18:1031-1033.
31. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107:294-299.
32. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780.
33. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA: Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized controlled trial. JAMA 2011, 305:1863-1872.
34. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, Akazawa K, Aizawa Y: Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction-randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010, 74:1415-1423.
35. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, Van't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, Van Gilst WH, Van Veldhuisen DJ: A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010, 31:2593-2600.